These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 4400174)

  • 1. Effect of decarboxylase inhibition and neuroleptic drugs on the DOPA level in rat brain.
    Cegrell L; Nordgren L; Rosengren AM
    Res Commun Chem Pathol Pharmacol; 1970 Jul; 1(4):479-84. PubMed ID: 4400174
    [No Abstract]   [Full Text] [Related]  

  • 2. Studies on the mechanism of the L-3,4-dihydroxyphenylalanine-induced decrease in tyrosine hydroxylase activity.
    Dairman W; Udenfriend S
    Mol Pharmacol; 1972 May; 8(3):293-9. PubMed ID: 4402746
    [No Abstract]   [Full Text] [Related]  

  • 3. Cerebral accumulation and metabolism of C14-dopa after selective inhibition of peripheral decarboxylase.
    Bartholini G; Pletscher A
    J Pharmacol Exp Ther; 1968 May; 161(1):14-20. PubMed ID: 5648492
    [No Abstract]   [Full Text] [Related]  

  • 4. Distribution of DOPA-2- 14 C in relation to DOPA-1- 14 C (carboxyl- 14 C-labelled DOPA) in mice before and after inhibition of DOPA-decarboxylase, studied by whole-body autoradiography.
    Tjälve H; Ullberg S
    Arch Int Pharmacodyn Ther; 1972 Oct; 199(2):376-88. PubMed ID: 4627124
    [No Abstract]   [Full Text] [Related]  

  • 5. Parkinson's disease: from brain homogenate to treatment.
    Hornykiewicz O
    Fed Proc; 1973 Feb; 32(2):183-90. PubMed ID: 4143953
    [No Abstract]   [Full Text] [Related]  

  • 6. Inhibition of dopa decarboxylation by RO4-4602, MK 485 and MK 486 in human liver homogenates.
    Vogel WH; Mahoney K; Hare TA
    Arch Int Pharmacodyn Ther; 1972; 198(1):85-93. PubMed ID: 4538242
    [No Abstract]   [Full Text] [Related]  

  • 7. Potentiation and inhbition of some central actions of L(-)-dopa by decarboxylase inhibitors.
    Lotti VJ; Porter CC
    J Pharmacol Exp Ther; 1970 Apr; 172(2):406-15. PubMed ID: 5441162
    [No Abstract]   [Full Text] [Related]  

  • 8. [Action of a decarboxylase inhibitor on endogenous plasmatic DOPA, in man].
    Geissbuhler F; Constantinidis J; Gaillard JM; des Combes NJ; Tissot R
    Biomedicine; 1974 Jul; 21(7):297-8. PubMed ID: 4433662
    [No Abstract]   [Full Text] [Related]  

  • 9. Aromatic amino acid decarboxylase inhibitors.
    Porter CC
    Fed Proc; 1971; 30(3):871-6. PubMed ID: 5575298
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of acute, repeated and chronic variable stress on in vivo tyrosine hydroxylase activity and on alpha(2)-adrenoceptor sensitivity in the rat brain.
    Prieto M; Gómez FM; Teresa Giralt M
    Stress; 2003 Dec; 6(4):281-7. PubMed ID: 14660060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modification of the cardiovascular effects of L-dopa by decarboxylase inhibitors.
    Watanabe AM; Parks LC; Kopin IJ
    J Clin Invest; 1971 Jun; 50(6):1322-8. PubMed ID: 5578236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of L-DOPA on brain polysomes and protein synthesis: probable mediation by intracellular dopamine.
    Weiss BF; Roel LE; Munro HN; Wurtman RJ
    Adv Neurol; 1974; 5():87-99. PubMed ID: 4155238
    [No Abstract]   [Full Text] [Related]  

  • 13. [Effect of neuroleptics on the content of dopamine and DOPAC in the caudate nucleus of the rat].
    Gérardy J; Dresse A
    Experientia; 1974 May; 30(5):523-4. PubMed ID: 4833680
    [No Abstract]   [Full Text] [Related]  

  • 14. [Progress in the therapy of parkinsonism with L-dopa: inhibition of dopa decarboxylase].
    Nurzia A
    Clin Ter; 1975 Feb; 72(3):289-95. PubMed ID: 1132216
    [No Abstract]   [Full Text] [Related]  

  • 15. [Neuroleptic therapy of schizophrenia from pharmacological viewpoint].
    Stille G
    Schweiz Med Wochenschr; 1969 Nov; 99(46):1645-52 contd. PubMed ID: 4391348
    [No Abstract]   [Full Text] [Related]  

  • 16. Modification of striatal acetylcholine concentration by dopamine receptor agonists and antagonists.
    Sethy VH; VAN Woert MH
    Res Commun Chem Pathol Pharmacol; 1974 May; 8(1):13-28. PubMed ID: 4847901
    [No Abstract]   [Full Text] [Related]  

  • 17. The dopamine-releasing actions of neuroleptics and ethanol.
    Seeman P; Lee T
    J Pharmacol Exp Ther; 1974 Jul; 190(1):131-40. PubMed ID: 4847309
    [No Abstract]   [Full Text] [Related]  

  • 18. [Inhibitors of catecholamine biosynthesis (review of the literature)].
    Frantsuzova SB
    Farmakol Toksikol; 1973; 36(5):624-8. PubMed ID: 4150865
    [No Abstract]   [Full Text] [Related]  

  • 19. [The measurement of tyrosine hydroxylase activity in the brain of conscious rats].
    Wang W; Zhao DZ; Wang WX; Sun BH
    Zhongguo Zhong Yao Za Zhi; 2002 Feb; 27(2):132-5. PubMed ID: 12774389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interpretation of effects of lesions on localization of brain monoamines.
    Moore RY
    Neurosci Res Program Bull; 1971 Mar; 9(2):258-63. PubMed ID: 4152629
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.